Table 5 Estimated cumulative breast cancer–free survival (six-marker definition) a
Intrinsic subtype | 2-year BCFS | 95% CI | 3-year BCFS | 95% CI | 5-year BCFS | 95% CI |
|---|---|---|---|---|---|---|
Luminal A | 96.7% | 95.2% to 98.3% | 92.8% | 90.6% to 95.0% | 85.8% | 82.7% to 88.9% |
Luminal B | 91.5% | 88.6% to 94.4% | 85.2% | 81.6% to 89.0% | 77.1% | 72.8% to 81.7% |
Luminal HER2 | 89.2% | 82.5% to 96.6% | 81.0% | 72.4% to 90.5% | 77.1% | 68.8% to 72.4% |
HER2-enriched | 72.4% | 62.5% to 83.8% | 63.9% | 53.5% to 76.3% | 58.3% | 47.6% to 71.5% |
Basal-like | 80.8% | 74.3% to 87.9% | 72.2% | 64.9% to 80.4% | 68.1% | 60.5% to 76.7% |
TNP nonbasal | 89.3% | 80.9% to 98.6% | 80.6% | 70.0% to 92.8% | 66.7% | 54.2% to 82.1% |